Article in Physiological reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Brooks A HibnerIntegrative Physiology Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0002-2830-4482
Natalia S LimaIntegrative Physiology Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0001-9430-1557
Sara R ShermanIntegrative Physiology Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0003-3456-5213
Robert W MotlIntegrative Physiology Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA.
Julio A ChirinosHospital of the University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Shane PhillipsDepartment of Physical Therapy, University of Illinois at Chicago, Chicago, Illinois, USA.
Philip S CliffordIntegrative Physiology Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0003-1849-3969
Anthony T RederDepartment of Neurology, University of Chicago Medicine, Chicago, Illinois, USA.
Tracy BaynardIntegrative Physiology Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA.
Bo FernhallIntegrative Physiology Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA.
Funding
Subclinical Vascular Contributions to Alzheimer's Disease: The Multi-Ethnic Study of Atherosclerosis (MESA) Multisite Study of AD (Renewal)R01AG058969 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Timothy M. Hughes, YONGMEI LIU · 2018 to 2026
$33.4M
VASCULAR EFFECTS OF DIETARY SALT IN HUMANS WITH SALT-RESISTANT BPR01HL104106 · NHLBI · UNIVERSITY OF DELAWARE · PI EDWARDS, DAVID G, FARQUHAR, WILLIAM B · 2011 to 2021
$4.5M
Targeting Skeletal Muscle Perfusion and Oxidative Capacity in HFpEFR01HL155599 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.9M
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 SurvivorsR01HL157108 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA, Jordana B. Cohen · 2022 to 2026
$3.9M
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)R01HL153646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2020 to 2024
$3.2M
Cardiovascular Consequences of Duchenne and Becker Muscular DystrophinopathiesR01HL155764 · NHLBI · UNIVERSITY OF DELAWARE · PI WITMAN, MELISSA A.H. · 2021 to 2025
$3.1M
Developing Oral LT3 Therapy for Heart FailureR33HL146390 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, ANNE R, CAPPOLA, THOMAS P. · 2020 to 2022
$2.2M
Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trialU01TR003734 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI CHIRINOS MEDINA, JULIO ALONSO · 2021 to 2021
$1.8M
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical CentersU01HL160277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA · 2021 to 2026
$1.7M
Genetic determinants of thoracic aortic stiffness and remodelingK24AG070459 · NIA · UNIVERSITY OF PENNSYLVANIA · PI CHIRINOS MEDINA, JULIO ALONSO · 2021 to 2025
$975k
American College of Sports Medicine (ACSM) 21-01556DOD | US Army | MEDCOM | Armed Forces Institute of Regenerative Medicine (AFIRM) W81XWH1810466NCATS NIH HHS U01 TR003734NHLBI NIH HHS R01 HL104106NHLBI NIH HHS R01 HL153646NHLBI NIH HHS R01 HL155599NHLBI NIH HHS R01 HL155764NHLBI NIH HHS R01 HL157108NHLBI NIH HHS R33 HL146390NHLBI NIH HHS U01 HL160277NIA NIH HHS K24 AG070459NIA NIH HHS R01 AG058969
6 · The paper itself
Abstract
Multiple sclerosis (MS) is a chronic neurological condition resulting in decreased aerobic capacity (peak VO
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosis. · full record | OpenQuestion